방사성 의약품 시장

Radiopharmaceuticals Market- Scope of Report

TMR's report on the global Radiopharmaceuticals Marketstudies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the Market during the forecast period from 2025 to 2035. The report provides revenue of the global Radiopharmaceuticals Marketfor the period 2025 to 2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Radiopharmaceuticals Marketfrom 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Radiopharmaceuticals Market .

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Radiopharmaceuticals Market .

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Radiopharmaceuticals Market . These serve as valuable tools for existing Market players as well as for entities interested in participating in the global Radiopharmaceuticals Market .

The report delves into the competitive landscape of the global Radiopharmaceuticals Market . Key players operating in the global Radiopharmaceuticals Markethave been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Radiopharmaceuticals Marketprofiled in this report.

Key Questions Answered in Global Radiopharmaceuticals MarketReport:

• What are the opportunities in the global Radiopharmaceuticals Market ?
• What are the major drivers, restraints, opportunities, and threats in the Market ?
• Which regional Market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2035?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the Market positions of different companies operating in the global Market ?

Radiopharmaceuticals Market- Research Objectives and Research Approach

The comprehensive report on the global Radiopharmaceuticals Marketbegins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the Market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the Market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Radiopharmaceuticals Marketin terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the Market share for each of these at the end of 2035 has been provided. Such valuable insights enable Market stakeholders in making informed business decisions for investment in the global Radiopharmaceuticals Market .

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Radiopharmaceuticals Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Radiopharmaceuticals Market Analysis and Forecast, 2020 to 2035
  • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

• 5.1. FDA Approved Radiopharmaceuticals Products
• 5.2. Epidemiology of Major Diseases
• 5.3. Reimbursement Scenario by key Countries/Regions
• 5.4. Pricing Analysis
• 5.5. Pipeline Analysis
• 5.6. Technological Advancements & Development
• 5.7. Insights on Pioneering Targeted in Radiotherapy
• 5.8. Regulatory Scenario by Country/Regions
• 5.9. Key Industry Events (Product Launch, Key Mergers and Acquisitions, etc.)
• 5.10. Number of Radiotherapy Centers: Major Country

6. Global Radiopharmaceuticals Market Analysis and Forecast, by Radioisotopes

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Radioisotopes, 2020 to 2035
  • 6.3.1. Diagnostics
    • 6.3.1.1. Fluorine-18 (F-18)
      • 6.3.1.1.1. Fludeoxyglucose (FDG)
      • 6.3.1.1.2. Sodium Fluoride
      • 6.3.1.1.3. Flucicovine
      • 6.3.1.1.4. Florbetapir
      • 6.3.1.1.5. Florbetaben
      • 6.3.1.1.6. Others
    • 6.3.1.2. Gallium-68 (Ga-68)
      • 6.3.1.2.1. Dotatate
      • 6.3.1.2.2. Dotatoc
      • 6.3.1.2.3. PSMA-11
    • 6.3.1.3. Technetium-99m (Tc-99)
    • 6.3.1.4. Iodine-123 (I-123)
    • 6.3.1.5. Others
  • 6.3.2. Therapy
    • 6.3.2.1. Iodine-131 (I-131)
    • 6.3.2.2. Yttrium-90 (Y-90)
    • 6.3.2.3. Lutetium-177 (Lu-177)
      • 6.3.2.3.1. Lu-PSMA-617
      • 6.3.2.3.2. Lu-DOTA-TATE
    • 6.3.2.4. Others
• 6.4. Market Attractiveness Analysis, by Radioisotopes

7. Global Radiopharmaceuticals Market Analysis and Forecast, by Application

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Application, 2020 to 2035
  • 7.3.1. Oncology
    • 7.3.1.1. Prostate Cancer
    • 7.3.1.2. Breast Cancer
    • 7.3.1.3. Neuroendocrine Tumors
    • 7.3.1.4. Thyroid Cancer
    • 7.3.1.5. Colorectal Cancer
    • 7.3.1.6. Liver Cancer
    • 7.3.1.7. Others
  • 7.3.2. Neurology
    • 7.3.2.1. Alzheimer's Disease
    • 7.3.2.2. Parkinson's Disease
    • 7.3.2.3. Others
  • 7.3.3. Cardiology
  • 7.3.4. Others
• 7.4. Market Attractiveness Analysis, by Application

8. Global Radiopharmaceuticals Market Analysis and Forecast, by End-user

• 8.1. Introduction & Definition
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by End-user, 2020 to 2035
  • 8.3.1. Hospitals
  • 8.3.2. Diagnostics and Imaging Centers
  • 8.3.3. Others
• 8.4. Market Attractiveness Analysis, by End-user

9. Global Radiopharmaceuticals Market Analysis and Forecast, by Region

• 9.1. Key Findings
• 9.2. Market Value Forecast, by Region, 2020 to 2035
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness Analysis, by Region

10. North America Radiopharmaceuticals Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast, by Radioisotopes, 2020 to 2035
  • 10.2.1. Diagnostics
    • 10.2.1.1. Fluorine-18 (F-18)
      • 10.2.1.1.1. Fludeoxyglucose (FDG)
      • 10.2.1.1.2. Sodium Fluoride
      • 10.2.1.1.3. Flucicovine
      • 10.2.1.1.4. Florbetapir
      • 10.2.1.1.5. Florbetaben
      • 10.2.1.1.6. Others
    • 10.2.1.2. Gallium-68 (Ga-68)
      • 10.2.1.2.1. Dotatate
      • 10.2.1.2.2. Dotatoc
      • 10.2.1.2.3. PSMA-11
    • 10.2.1.3. Technetium-99m (Tc-99)
    • 10.2.1.4. Iodine-123 (I-123)
    • 10.2.1.5. Others
  • 10.2.2. Therapy
    • 10.2.2.1. Iodine-131 (I-131)
    • 10.2.2.2. Yttrium-90 (Y-90)
    • 10.2.2.3. Lutetium-177 (Lu-177)
      • 10.2.2.3.1. Lu-PSMA-617
      • 10.2.2.3.2. Lu-DOTA-TATE
    • 10.2.2.4. Others
• 10.3. Market Value Forecast, by Application, 2020 to 2035
  • 10.3.1. Oncology
    • 10.3.1.1. Prostate Cancer
    • 10.3.1.2. Breast Cancer
    • 10.3.1.3. Neuroendocrine Tumors
    • 10.3.1.4. Thyroid Cancer
    • 10.3.1.5. Colorectal Cancer
    • 10.3.1.6. Liver Cancer
    • 10.3.1.7. Others
  • 10.3.2. Neurology
    • 10.3.2.1. Alzheimer's Disease
    • 10.3.2.2. Parkinson's Disease
    • 10.3.2.3. Others
  • 10.3.3. Cardiology
  • 10.3.4. Others
• 10.4. Market Value Forecast, by End-user, 2020 to 2035
  • 10.4.1. Hospitals
  • 10.4.2. Diagnostics and Imaging Centers
  • 10.4.3. Others
• 10.5. Market Value Forecast, by Country, 2020 to 2035
  • 10.5.1. U.S.
  • 10.5.2. Canada
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Radioisotopes
  • 10.6.2. By Application
  • 10.6.3. By End-user
  • 10.6.4. By Country

11. Europe Radiopharmaceuticals Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Radioisotopes, 2020 to 2035
  • 11.2.1. Diagnostics
    • 11.2.1.1. Fluorine-18 (F-18)
      • 11.2.1.1.1. Fludeoxyglucose (FDG)
      • 11.2.1.1.2. Sodium Fluoride
      • 11.2.1.1.3. Flucicovine
      • 11.2.1.1.4. Florbetapir
      • 11.2.1.1.5. Florbetaben
      • 11.2.1.1.6. Others
    • 11.2.1.2. Gallium-68 (Ga-68)
      • 11.2.1.2.1. Dotatate
      • 11.2.1.2.2. Dotatoc
      • 11.2.1.2.3. PSMA-11
    • 11.2.1.3. Technetium-99m (Tc-99)
    • 11.2.1.4. Iodine-123 (I-123)
    • 11.2.1.5. Others
  • 11.2.2. Therapy
    • 11.2.2.1. Iodine-131 (I-131)
    • 11.2.2.2. Yttrium-90 (Y-90)
    • 11.2.2.3. Lutetium-177 (Lu-177)
      • 11.2.2.3.1. Lu-PSMA-617
      • 11.2.2.3.2. Lu-DOTA-TATE
    • 11.2.2.4. Others
• 11.3. Market Value Forecast, by Application, 2020 to 2035
  • 11.3.1. Oncology
    • 11.3.1.1. Prostate Cancer
    • 11.3.1.2. Breast Cancer
    • 11.3.1.3. Neuroendocrine Tumors
    • 11.3.1.4. Thyroid Cancer
    • 11.3.1.5. Colorectal Cancer
    • 11.3.1.6. Liver Cancer
    • 11.3.1.7. Others
  • 11.3.2. Neurology
    • 11.3.2.1. Alzheimer's Disease
    • 11.3.2.2. Parkinson's Disease
    • 11.3.2.3. Others
  • 11.3.3. Cardiology
  • 11.3.4. Others
• 11.4. Market Value Forecast, by End-user, 2020 to 2035
  • 11.4.1. Hospitals
  • 11.4.2. Diagnostics and Imaging Centers
  • 11.4.3. Others
• 11.5. Market Value Forecast, by Country/Sub-region, 2020 to 2035
  • 11.5.1. Germany
  • 11.5.2. UK
  • 11.5.3. France
  • 11.5.4. Italy
  • 11.5.5. Spain
  • 11.5.6. Switzerland
  • 11.5.7. The Netherlands
  • 11.5.8. Rest of Europe
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Radioisotopes
  • 11.6.2. By Application
  • 11.6.3. By End-user
  • 11.6.4. By Country/Sub-region

12. Asia Pacific Radiopharmaceuticals Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Radioisotopes, 2020 to 2035
  • 12.2.1. Diagnostics
    • 12.2.1.1. Fluorine-18 (F-18)
      • 12.2.1.1.1. Fludeoxyglucose (FDG)
      • 12.2.1.1.2. Sodium Fluoride
      • 12.2.1.1.3. Flucicovine
      • 12.2.1.1.4. Florbetapir
      • 12.2.1.1.5. Florbetaben
      • 12.2.1.1.6. Others
    • 12.2.1.2. Gallium-68 (Ga-68)
      • 12.2.1.2.1. Dotatate
      • 12.2.1.2.2. Dotatoc
      • 12.2.1.2.3. PSMA-11
    • 12.2.1.3. Technetium-99m (Tc-99)
    • 12.2.1.4. Iodine-123 (I-123)
    • 12.2.1.5. Others
  • 12.2.2. Therapy
    • 12.2.2.1. Iodine-131 (I-131)
    • 12.2.2.2. Yttrium-90 (Y-90)
    • 12.2.2.3. Lutetium-177 (Lu-177)
      • 12.2.2.3.1. Lu-PSMA-617
      • 12.2.2.3.2. Lu-DOTA-TATE
    • 12.2.2.4. Others
• 12.3. Market Value Forecast, by Application, 2020 to 2035
  • 12.3.1. Oncology
    • 12.3.1.1. Prostate Cancer
    • 12.3.1.2. Breast Cancer
    • 12.3.1.3. Neuroendocrine Tumors
    • 12.3.1.4. Thyroid Cancer
    • 12.3.1.5. Colorectal Cancer
    • 12.3.1.6. Liver Cancer
    • 12.3.1.7. Others
  • 12.3.2. Neurology
    • 12.3.2.1. Alzheimer's Disease
    • 12.3.2.2. Parkinson's Disease
    • 12.3.2.3. Others
  • 12.3.3. Cardiology
  • 12.3.4. Others
• 12.4. Market Value Forecast, by End-user, 2020 to 2035
  • 12.4.1. Hospitals
  • 12.4.2. Diagnostics and Imaging Centers
  • 12.4.3. Others
• 12.5. Market Value Forecast, by Country/Sub-region, 2020 to 2035
  • 12.5.1. China
  • 12.5.2. Japan
  • 12.5.3. India
  • 12.5.4. South Korea
  • 12.5.5. Australia & Newzealend
  • 12.5.6. Rest of Asia Pacific
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Radioisotopes
  • 12.6.2. By Application
  • 12.6.3. By End-user
  • 12.6.4. By Country/Sub-region

13. Latin America Radiopharmaceuticals Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Radioisotopes, 2020 to 2035
  • 13.2.1. Diagnostics
    • 13.2.1.1. Fluorine-18 (F-18)
      • 13.2.1.1.1. Fludeoxyglucose (FDG)
      • 13.2.1.1.2. Sodium Fluoride
      • 13.2.1.1.3. Flucicovine
      • 13.2.1.1.4. Florbetapir
      • 13.2.1.1.5. Florbetaben
      • 13.2.1.1.6. Others
    • 13.2.1.2. Gallium-68 (Ga-68)
      • 13.2.1.2.1. Dotatate
      • 13.2.1.2.2. Dotatoc
      • 13.2.1.2.3. PSMA-11
    • 13.2.1.3. Technetium-99m (Tc-99)
    • 13.2.1.4. Iodine-123 (I-123)
    • 13.2.1.5. Others
  • 13.2.2. Therapy
    • 13.2.2.1. Iodine-131 (I-131)
    • 13.2.2.2. Yttrium-90 (Y-90)
    • 13.2.2.3. Lutetium-177 (Lu-177)
      • 13.2.2.3.1. Lu-PSMA-617
      • 13.2.2.3.2. Lu-DOTA-TATE
    • 13.2.2.4. Others
• 13.3. Market Value Forecast, by Application, 2020 to 2035
  • 13.3.1. Oncology
    • 13.3.1.1. Prostate Cancer
    • 13.3.1.2. Breast Cancer
    • 13.3.1.3. Neuroendocrine Tumors
    • 13.3.1.4. Thyroid Cancer
    • 13.3.1.5. Colorectal Cancer
    • 13.3.1.6. Liver Cancer
    • 13.3.1.7. Others
  • 13.3.2. Neurology
    • 13.3.2.1. Alzheimer's Disease
    • 13.3.2.2. Parkinson's Disease
    • 13.3.2.3. Others
  • 13.3.3. Cardiology
  • 13.3.4. Others
• 13.4. Market Value Forecast, by End-user, 2020 to 2035
  • 13.4.1. Hospitals
  • 13.4.2. Diagnostics and Imaging Centers
  • 13.4.3. Others
• 13.5. Market Value Forecast, by Country/Sub-region, 2020 to 2035
  • 13.5.1. Brazil
  • 13.5.2. Mexico
  • 13.5.3. Argentina
  • 13.5.4. Rest of Latin America
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Radioisotopes
  • 13.6.2. By Application
  • 13.6.3. By End-user
  • 13.6.4. By Country/Sub-region

14. Middle East & Africa Radiopharmaceuticals Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Radioisotopes, 2020 to 2035
  • 14.2.1. Diagnostics
    • 14.2.1.1. Fluorine-18 (F-18)
      • 14.2.1.1.1. Fludeoxyglucose (FDG)
      • 14.2.1.1.2. Sodium Fluoride
      • 14.2.1.1.3. Flucicovine
      • 14.2.1.1.4. Florbetapir
      • 14.2.1.1.5. Florbetaben
      • 14.2.1.1.6. Others
    • 14.2.1.2. Gallium-68 (Ga-68)
      • 14.2.1.2.1. Dotatate
      • 14.2.1.2.2. Dotatoc
      • 14.2.1.2.3. PSMA-11
    • 14.2.1.3. Technetium-99m (Tc-99)
    • 14.2.1.4. Iodine-123 (I-123)
    • 14.2.1.5. Others
  • 14.2.2. Therapy
    • 14.2.2.1. Iodine-131 (I-131)
    • 14.2.2.2. Yttrium-90 (Y-90)
    • 14.2.2.3. Lutetium-177 (Lu-177)
      • 14.2.2.3.1. Lu-PSMA-617
      • 14.2.2.3.2. Lu-DOTA-TATE
    • 14.2.2.4. Others
• 14.3. Market Value Forecast, by Application, 2020 to 2035
  • 14.3.1. Oncology
    • 14.3.1.1. Prostate Cancer
    • 14.3.1.2. Breast Cancer
    • 14.3.1.3. Neuroendocrine Tumors
    • 14.3.1.4. Thyroid Cancer
    • 14.3.1.5. Colorectal Cancer
    • 14.3.1.6. Liver Cancer
    • 14.3.1.7. Others
  • 14.3.2. Neurology
    • 14.3.2.1. Alzheimer's Disease
    • 14.3.2.2. Parkinson's Disease
    • 14.3.2.3. Others
  • 14.3.3. Cardiology
  • 14.3.4. Others
• 14.4. Market Value Forecast, by End-user, 2020 to 2035
  • 14.4.1. Hospitals
  • 14.4.2. Diagnostics and Imaging Centers
  • 14.4.3. Others
• 14.5. Market Value Forecast, by Country/Sub-region, 2020 to 2035
  • 14.5.1. GCC Countries
  • 14.5.2. South Africa
  • 14.5.3. Rest of Middle East & Africa
• 14.6. Market Attractiveness Analysis
  • 14.6.1. By Radioisotopes
  • 14.6.2. By Application
  • 14.6.3. By End-user
  • 14.6.4. By Country/Sub-region

15. Competition Landscape

• 15.1. Market Player - Competition Matrix (By Tier and Size of Companies)
• 15.2. Market Share Analysis, by Company (2024)
• 15.3. Company Profiles
  • 15.3.1. Advanced Accelerator Applications
    • 15.3.1.1. Company Overview
    • 15.3.1.2. Financial Overview
    • 15.3.1.3. Product Portfolio
    • 15.3.1.4. Business Strategies
    • 15.3.1.5. Recent Developments
  • 15.3.2. Bayer AG
    • 15.3.2.1. Company Overview
    • 15.3.2.2. Financial Overview
    • 15.3.2.3. Product Portfolio
    • 15.3.2.4. Business Strategies
    • 15.3.2.5. Recent Developments
  • 15.3.3. Eli Lilly and Company
    • 15.3.3.1. Company Overview
    • 15.3.3.2. Financial Overview
    • 15.3.3.3. Product Portfolio
    • 15.3.3.4. Business Strategies
    • 15.3.3.5. Recent Developments
  • 15.3.4. GE Healthcare
    • 15.3.4.1. Company Overview
    • 15.3.4.2. Financial Overview
    • 15.3.4.3. Product Portfolio
    • 15.3.4.4. Business Strategies
    • 15.3.4.5. Recent Developments
  • 15.3.5. ITM Isotopen Technologien Munchen AG
    • 15.3.5.1. Company Overview
    • 15.3.5.2. Financial Overview
    • 15.3.5.3. Product Portfolio
    • 15.3.5.4. Business Strategies
    • 15.3.5.5. Recent Developments
  • 15.3.6. Jubilant Pharma Limited
    • 15.3.6.1. Company Overview
    • 15.3.6.2. Financial Overview
    • 15.3.6.3. Product Portfolio
    • 15.3.6.4. Business Strategies
    • 15.3.6.5. Recent Developments
  • 15.3.7. Lantheus Holdings, Inc.
    • 15.3.7.1. Company Overview
    • 15.3.7.2. Financial Overview
    • 15.3.7.3. Product Portfolio
    • 15.3.7.4. Business Strategies
    • 15.3.7.5. Recent Developments
  • 15.3.8. Nihon Medi-Physics
    • 15.3.8.1. Company Overview
    • 15.3.8.2. Financial Overview
    • 15.3.8.3. Product Portfolio
    • 15.3.8.4. Business Strategies
    • 15.3.8.5. Recent Developments
  • 15.3.9. Siemens Healthineers AG
    • 15.3.9.1. Company Overview
    • 15.3.9.2. Financial Overview
    • 15.3.9.3. Product Portfolio
    • 15.3.9.4. Business Strategies
    • 15.3.9.5. Recent Developments
  • 15.3.10. Telix Pharmaceuticals
    • 15.3.10.1. Company Overview
    • 15.3.10.2. Financial Overview
    • 15.3.10.3. Product Portfolio
    • 15.3.10.4. Business Strategies
    • 15.3.10.5. Recent Developments